The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis

PharmacoEconomics

Volumn 10, Issue 2, 1996, Pages 141-151

  Al, Maiwenn J ^a   Michel, Bowine C ^a   Rutten, Frans F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MISOPROSTOL;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; MODEL; PEPTIC ULCER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029779881     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610020-00006     Document Type: Article

References (41)

1. Valkenburg HA. Rheumatoid arthritis. In: Grobbee DE, Hofman A, editors. Epidemiology of diseases in the Netherlands [in Dutch]. Utrecht: Wetenschappelijke uitgeverij Bunge, 1980: 200-5
2. Koopmanschap MA, van Roijen L, Bonneux L. Costs of illness in the Netherlands [in Dutch]. Rotterdam: Erasmus University, 1991
3. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; II: 1277-80
4. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
5. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639-46
6. Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234-44
7. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990 264: 41-7
8. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-59
9. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-82
10. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? Arch Intern Med 1994; 154: 2020-5
11. Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 85-91
12. Bolten W, Melo Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31: 753-8
13. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-62
14. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/ misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881-5
15. Barradell LB, Whittington R, Benfield P. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. PharmacoEconomics 1993; 3: 140-70
16. Silverstein F, Graham DY, Senior JR, et al. Misoprostol reduces the frequency of serious gastrointestinal complications in chronic nonsteroidal anti-inflammatory drug use: randomized double-blind controlled trial in patients with rheumatoid arthritis. Ann Intern Med 1995; 123: 241-9
17. de Pouvourville G. Preventing NSAID-induced gastrointestinal toxicity: economic considerations, methodological problems and results. PharmacoEconomics 1995; 7: 99-110
18. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-2
19. Geis GS. Overall safety of Arthrotec®. Scand J Rheumatol 1992; Suppl. 96: 33-6
20. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol 1989; 24 Suppl. 163: 3-8
21. Eversmeyer W, Poland M, DeLapp RE, et al. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95 Suppl. 2A: 10S-8S
22. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8
23. Farah D, Sturrock RD, Russell RI. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 478-80
24. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32
25. Jorde R, Burhol PG, Johnson JA. Peptic ulcer bleeding in patients with and without dyspepsia. Scand J Gastroenterol 1988; 23: 213-6
26. SIG Zorginformatie. SIG Yearbook Hospitals 1991 [in Dutch]. Utrecht: SIG Zorginformatie, 1993
27. De Nederlandse Lever Darm Stichting. Diseases of the digestive tract in the Netherlands, 1970-1989 [in Dutch]. Breukelen: De Nederlandse Lever Darm Stichting, 1992
28. McCarthy DM. Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 1989; 96: 662-74
29. Mellem H, Stave R, Myren J, et al. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid anti-inflammatory drugs. Scand J Gastroenterol 1985; 20: 1246-8
30. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 Suppl. 28: 6-10
31. Van Berge Henegouwen GP, Bijlsma JWJ. Therapeutic policy for NSAID-induced ulcers [in Dutch]. Ned Tijdschr Geneeskd 1991; 135: 504-8
32. McGuigan JE. Peptic ulcer and gastritis. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 1994
33. COTG (Central Organisation on Tariffs in Health Care). Vademecum [in Dutch]. Alphen aan den Rijn, 1995
34. Netherlands Central Bureau of Statistics. Monthly bulletin of population. December 1993 [in Dutch]. The Hague: Netherlands Central Bureau of Statistics, 1993
35. Vandenbrouke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow up. J Rheumatol 1984; 11: 158-61
36. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
37. Dutch Health Insurance Funds Council. Pharmacotherapeutical Compass 1995 [in Dutch]. Amstelveen: Dutch Health Insurance Funds Council, 1995
38. Organisation for Economic Cooperation and Development (OECD). Financing and delivering health care: a comparative analysis of OECD countries. Paris: OECD, 1987
39. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991; 49: 531-7
40. van Ballegooijen M, Habbema JDF, van Oortmarssen GJ, et al. Preventive pap-smear: balancing costs, risks and benefits. Br J Cancer 1992; 65: 903-33
41. Martens LL, Rutten FFH, Erkelens DW, et al. Cost-effectiveness of cholesterol lowering therapy in the Netherlands: simvastatin versus cholestyramine. Am J Med 1989; 87: 54S-8S